BioSpace News Archive

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced its results for the year ended December 31, 2020 and provided a corporate update.

Due to concerns regarding the coronavirus outbreak and to assist in protecting the health and well-being of our shareholders and employees, this year’s Annual Meeting of Shareholders of Stryker Corporation will be held virtually via the internet.

Investments towards promotion of fertility treatment services aimed towards international clients is likely to remain key to growth strategies in terms of sales in a fairly competitive industry.

A sedentary lifestyle, unhealthy eating habits, and growing stress levels are increasingly responsible for severe hair loss and damage, also known as alopecia.

The lifesaving function of stents, which are small mesh tubes inserted inside blocked arteries to open up the passage for blood to travel from the heart to other parts of the body, have resulted in their swift sales.

Medical pendants form a key part of medical infrastructure in hospitals and clinics to improve the workflows, prevent any cross-contamination, and improve the ergonomics.

Growing worldwide population living with numerous disease conditions is projected to stimulate fabulous demand opportunities in the US therapeutic plasma exchange market during 2019–2029.

Myovant Sciences and Pfizer Inc. announced positive data from the Phase 3 LIBERTY randomized withdrawal study of relugolix combination therapy in women with uterine fibroids.

Mallinckrodt plc announced that employees Tanya Hill, Executive Director, Commercial Strategy and Brand Planning, will be honored as a Luminary; and Megan Roberts, Director, SEC Reporting, Technical Accounting, and Global Consolidations, will be honored as a Rising Star by the Healthcare Businesswomen’s Association at its 32nd Annual Woman of the Year virtual event, on May 6, 2021.

Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Leen Kawas, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at Stifel’s 3 rd Annual CNS Conference on Thursday, April 1, 2021, at 9:00 am ET.